Nonspecific biomolecular nucleophiles

Nonspecific biomolecular nucleophiles refer to a broad category of cellular components, including DNA, RNA, and various proteins, that contain electron-rich functional groups such as thiols, amines, and phosphates (DrugBank, 2024). In pharmacology, this term is used to describe the collective targets of highly reactive electrophilic drugs, most notably the alkylating agents used in cancer chemotherapy (StatPearls, 2023). These drugs exert their therapeutic effects by forming strong covalent bonds with nucleophilic sites, with the N7 position of guanine in DNA being a primary target for cross-linking (PubMed, 2022). This modification disrupts DNA replication and transcription, ultimately triggering programmed cell death in rapidly dividing malignant cells (NIH, 2023). Because these interactions are not restricted to a single specific protein or receptor, they are characterized as 'nonspecific,' which contributes to their broad-spectrum efficacy as well as their significant systemic side effects (NCBI, 2021). Common toxicities associated with hitting these targets include myelosuppression and the risk of developing secondary cancers due to the mutagenic nature of DNA alkylation (PubMed, 2023). Despite the advent of targeted therapies, drugs interacting with nonspecific biomolecular nucleophiles remain a cornerstone of many oncology regimens.

Other names

Cellular nucleophilesEndogenous nucleophilesBiomolecular nucleophilic sitesNucleophilic cellular targets

Drugs targeting these nucleophiles act via covalent modification (alkylation or platination) of electron-rich functional groups such as amino, sulfhydryl, carboxyl, and phosphate groups, primarily within DNA, leading to cross-linking and strand breaks.